128 results about "Roxithromycin" patented technology

The present invention provides compositions and methods for extending the release times and lowering the toxicity of pharmacologically active compounds. The compounds comprise a salt of the pharmacologically active compound with a lipophilic counterion and a pharmaceutically acceptable water soluble solvent combined together to form an injectable composition. The lipophilic counterion may be a saturated or unsaturated C₈-C₂₂ fatty acid, and preferably may be a saturated or unsaturated C₁₀-C₁₈ fatty acid. The compounds precipitate in aqueous environments. When injected into a mammal, at least a portion of the composition precipitates and releases the active compound over time. Thus, the composition forms a slowly releasing drug depot of the active compound in the mammal. Therefore, the present invention enables one to provide a controlled dose administration of the active compound for a period of up to 15 days or even longer. Many compounds can be administered according to the present invention including, but not limited to, tilmicosin, oxytetracycline, metoprolol, fluoxetine, roxithromycin, and turbinafine.

The invention relates to detection of a pair of babesiidae protozoon detection primer, and the upstream and downstream primer sequences are shown as SEQ ID No.1 and SEQ ID No.2. A real-time fluorescent PCR (polymerase chain reaction) kit for babesiidae protozoon detection comprises a Taq (thermu aquaticus) DNA polymerase mixed liquid, a ROX (roxithromycin) dye, a primer 1 with a nucleotide sequence shown as the SEQ ID No.1, a primer 2 with a nucleotide sequence shown as the SEQ ID No.2, a TaqMan probe with a nucleotide sequence shown as SEQ ID No.3, a negative control and a positive control. The provided real-time fluorescent quantitative PCR detection kit is convenient to use, is less in reagent use amount, greatly simplifies the operation process, reduces pollution in the operation process, is strong in detection effect specificity and is high in sensitivity.

The invention discloses application of papermaking sludge based biological carbon in removal of antibiotics or heavy metals and the antibiotics from a water body and belongs to the technical field ofbiomass treatment and water treatment. The papermaking sludge based biological carbon has larger specific area and a larger pore size and can efficiently remove combined pollution of copper, zinc, arsenic, sulfadimidine, tylosin and roxithromycin. The biological carbon is simple in preparation technology, significant and stable in effect, environment-friendly and free from secondary pollution, andhas a wide application value in a heavy metal/antibiotic pollution repair aspect in the water body. Paper mill sludge difficult to treat is recycled; the environmental pollution problems of wastewater containing the heavy metals and the antibiotics are solved; and therefore, the application has important environmental and economic benefits. The biological carbon has a huge market and an application potential in waste recycling and sewage treatment.

A penetrating antibiotic gel for treating pain, inflammation and other pathological conditions affecting musculoskeletal tissues and other soft tissues of the body. The composition includes an antibiotic compound and a mobilizing agent in an amount sufficient to enable the antimicrobial compound to penetrate into the sub-dermal soft tissues. The antimicrobial compound may be a macrolide antibiotic compound such as azithromycin, erythromycin or roxithromycin, for example, and the mobilizing agent may be an organogel compound, such as pluronic lecithin liposomal organogel (PLO). The composition may further include a penetration enhancing adjuvant, such as d-limonene, for example. The composition may be applied topically so as to penetrate into the sub-dermal soft tissues, or may injected so as to be absorbed into the soft tissues locally.

The invention relates to the technical field of environment detection and is suitable for measuring erythrocin, chloramphenicol, sulfamethoxazole, sulfadiazine, roxithromycin, cefotiam, pyridazol, norfloxacin, ofloxacin, tetracycline and doxycycline in sewage, surface water and bottom mud. After being sampled, a water sample and a mud sample are pretreated and detected through ultra-high performance liquid chromatography-triple quadrupole mass spectrometry, and qualitative diagnosis is conducted through the characteristic ion pair (m/z) of a target compound, a standard curve is drawn accordingto the response value and the corresponding concentration, and the external standard method is used in quantification, so that the contents of various antibiotics in the sample are obtained. The method is accurate, sensitive and simple, and is suitable for measuring the contents of 11 typical antibiotics in the sewage, the surface water and the mud at the same time.

A coated roxithromycin microsoftgel is disclosed. Its fluidized-bed preparing method features that the solution of the copolymer of dimethylamino ethyl methylacrylate and methylacrylate in alcohol is used as the coating material to coat the roxithromycin in fluidized-bed granulator, and then is dried in hot airflow. Its advantages are no bitter taste, easy absorption in stomach and no environmental pollution.

The invention relates to a fluorescence PCR (polymerase chain reaction) kit for detecting yersinia enterocolitica, reagents in the kit comprise a front primer, a rear primer, a TaqMan probe, a fluorescence PCR premixed solution, an ROX (roxithromycin) solution, pure water and a positive standard solution, wherein the front primer, the rear primer and the TaqMan probe are DNA (deoxyribonucleic acid) fragments of 20-21 bases, which are synthesized according to a specific and conserved gene nucleotide sequence of the yersinia enterocolitica and can be specifically combined with the yersinia enterocolitica. The invention further provides a method for detecting the yersinia enterocolitica, and the method comprises the following steps: performing pretreatment on samples; using the reagents of the kit for detection; and analyzing the detection result. The kit is simple, fast, sensitive, accurate and suitable for detecting a large number of samples.

The invention discloses enterococcus faecium collected in the China General Microbiological Culture Collection Center (CGMCC), with collection number being CGMCC No.10575. The enterococcus faecium has the technical effects that lactobacillus with an erythromycin and roxithromycin degrading function is screened from soil through preliminary screening and secondary screening of an antibiotic selective medium; a reasonable and effective screening method of an erythromycin and roxithromycin degrading strain is established to obtain lactobacillus meeting the needs; the safe and effective erythromycin and roxithromycin degrading strain is screened through separation, purification and screening of lactobacillus and a series of work, such as preliminary screening and secondary screening of erythromycin and roxithromycin degrading lactobacillus; when applied to control over erythromycin and roxithromycin pollution, the enterococcus faecium has the advantages of no secondary pollution, high treatment efficiency, wide range of application and low cost; the enterococcus faecium provides more choices for microbiological control over antibiotic pollution of complex environments.

The invention relates to an orally disintegrating tablet comprising roxithromycin id and ambroxol hydrochloride as active ingredients and its preparation method and uses. Said invention is a medical compound resulting from mixing roxithromycin id and ambroxol hydrochloride as active ingredients and auxiliary material acceptable by pharmacology and for treatment of infection of the upper respiratory tract. Said invention provides means for covering bitter from roxithromycin id and ambroxol hydrochloride and preparation method for orally disintegrating tablets of said medical compound.

The invention relates to a roxithromycin monohydrate crystal, a preparation method thereof and a compound dry suspension containing the roxithromycin monohydrate crystal and an ambroxol hydrochloride composition. The roxithromycin monohydrate crystal provided by the invention has a molecular formula of C41H76N2O15.H2O. The preparation method comprises the steps of sample dissolving, devitrifying,smashing, water exchanging and drying. The invention also provides a composition containing the crystal, and the composition comprises 30-70 parts by weight of roxithromycin monohydrate crystals, 5-15 parts by weight of ambroxol hydrochloride, 10-30 parts by weight of xanthan gum, 10-50 parts by weight of hydroxypropyl methylcellulose, 2870-2920 parts by weight of cane sugar and a proper amount of banana essence. The crystal provided by the invention has low moisture absorption and good stability. The composition provided by the invention contains the roxithromycin monohydrate crystal, the suspension is in a good condition, the dissolution rate of medicaments is increased, and the bioavailability is improved.

The present invention relates to Roxithromycin injection and is especially bacteria-free powder and solution of water soluble Roxithromycin salt, such as Roxithromycin hydrochloride, Roxithromycin tartrate and Roxithromycin lactobionate, for injection. The present invention also provides the preparation process of bacteria-free powder and solution of water soluble Roxithromycin salt for injection.

The invention discloses a novel roxithromycin capsule, which comprises the following components in percentage by weight: 55-70% of roxithromycin, 3-6% of a binder, 15-20% of a coating material, and 6% of a plasticizer. ~8%, porogen 5~9%, glidant 0.5~1.5%. The invention also discloses a preparation method of the novel roxithromycin capsule. The roxithromycin capsule of the present invention greatly improves the disadvantages of the common oral dosage form of roxithromycin, which are frequently taken and have low bioavailability. Roxithromycin was made into pellets, and the roxithromycin pellets were made into sustained-release tablets by an improved fluidized bed coating method, and then filled into capsules to obtain roxithromycin sustained-release capsules. The operation is simple and reproducible. Well, it is easy to achieve mass production, and compared with other commercially available sustained-release capsule dosage forms, through the re-vulcanization process after fluidized coating, the coating material can exert a sustained-release effect, so as to achieve better curative effect.

A showly-releasing roxithromycin contains roxithromycin (30-80 wt.%), slow-releasing assistant (hydroxypropylmethyl cellulose, etc) (10-40 wt.%), and others (hole-forming agent, adhesive, lubricant, etc). Its advantages are long active period (24 hrs.), and low by-effect.

An orally absorbed medicine in the form of buccal lozenge, sweets, or dripping pill dissolved by saliva features that it contains roxithromycin. Its preparing process is also disclosed.

The invention mainly discloses a method for purifying roxithromycin. The method comprises the following steps of dispersing erythromycin crude products into a mixed solvent of two lower alcohols, heating to clarify the mixed liquid obtained from the above step, cooling to make precipitates be separated from the clarified liquid obtained from the above step and stirring at a low temperature for a period of time to make the precipitates be separated from the clarified liquid fully, and filtering to obtain purified erythromycin. The method has the advantages of good impurity removal effects, high yield, continuous use feature of mother liquor, few three wastes, low cost, good adaptability for industrialization production, and favorable products with uniform granularity, good fluidity, a small number of broken crystals, and high hardness of crystals.

The invention relates to a roxithromycin capsule and a preparation method of the roxithromycin capsule. The roxithromycin capsule is prepared from the following constituents in percentage by weight:50-75 % of roxithromycin, 5-25 % of corn starch, 10-30 % of low-substituted hydroxypropyl cellulose, 0.5-6 % of a wetting agent, 0.5-3 % of a binder, and 0.5-3 % of a lubricant, wherein the binder ispolyvinylpyrrolidone; the wetting agent is selected from sodium dodecyl sulfate, Tween 80 and poloxamer; and the lubricant is selected from one or more of micropowder silica gel, magnesium stearate and talcum powder.

The invention relates to a roxithromycin ambroxol dispersing tablet, which comprises the following components in percentage by weight: 50 to 60 percent of roxithromycin, 10 to 20 percent of ambroxol hydrochloride, 18 to 25 percent of filling agent, 10 to 15 percent of disintegrant, 0.1 to 1 percent of adhesive, and 1 to 5 percent of lubricating agent, wherein the filling agent is microcrystalline cellulose, and the disintegrant is crosslinked polyvidone. The roxithromycin ambroxol dispersing tablet has the advantages of small tablet weight, simple process, low production cost and good safety, and has better therapeutic effect when being clinically applied to upper respiratory tract infections of human bodies.

A pharmaceutical with an enhanced pharmaceutical profile comprises a mucolytic and an antibiotic in which the mucolytic is present in an amount of greater than one molar equivalent of the antibiotic. The antibiotic may be selected from Erythromycin, Roxithromycin, Clarithromycin, Azithromycin, Dirithromycin; and pharmaceutically acceptable salts or esters thereof. The mucolytic is a mucolytically active thiol, especially N-acetylcysteine, mercaptoethanesulfonic acid, tiopronin or methylcysteine. The adducts can be isolated via a simple and efficient process.

The invention relates to the fields of analytical chemistry and food safety, and provides a detection method of the residual amount of a plurality of macrolide veterinary drugs in casings. The detection method comprises the following steps of: extracting a sample with methanol or acetonitrile; purifying the obtained extracting solution by a C18 or Oasis HLB (hydrophilic-lipophilic balance) solid-phase extraction column, taking an acetonitrile-methanoic acid aqueous solution with the concentration of 0.15% as a mobile phase, and performing gradient elution by adopting a ZORBAX Eclipse C8 analytical column; and performing electro-spraying, separating by a cationic scanning mode and detecting the residual amount of seven types of macrolide veterinary drugs. The detection lower limit of the seven types of macrolide veterinary drugs is 20 mu g/kg. The recovery rates of spiramycin, tilmicosin, oleandomycin, tylosin, erythrocin, roxithromycin and josamycin are respectively 71.4-78.8, 75.7-85.6, 81.1-85.8, 78.9-83.0, 87.1-89.6, 83.7-85.4 and 75.6-81.8; and the indoor relative standard deviations for the recovery rates of the spiramycin, the tilmicosin, the oleandomycin, the tylosin, the erythrocin, the roxithromycin and the josamycin are respectively 7.7-11.1, 8.0-15.7, 10.5-16.4, 8.1-12.5, 10.5-12.4, 10.6-14.4 and 7.8-18.0. The detection limit, the recovery rate, the precision and the like meet the related requirements at home and abroad.

The invention provides a novel method for separating/enriching trace roxithromycin in environment. The method comprises the following steps: adding 0.4mg.mL<-1> researched roxithromycin test solution in a mouth polished colorimetric tube, wherein the volume of the roxithromycin test solution accounts for 1/50 of total volume of total solution in sublation; adding solid salt to adjust the ionic strength of the solution, shaking the solution to ensure that the solution can be sufficiently dissolved, and adjusting pH to be between 10.8 and 11.8, wherein the salt is solid salt of Na2CO3, (NH4)2SO4, NaH2PO4, MgSO4, Na2SO3 and NaOH; transferring the solution into a sublation column, adding the sublation solvent ionic liquid [Bmim]BF4 into the sublation column, and bringing to total volume by adding water, wherein the volume of the ionic liquid [Bmim]BF4 accounts for 1/25 of total volume of total solution in sublation, and the sublation flow rate of N2 is between 5 and 25mL.min<-1>; floating for 5 to 60 minutes, standing for 1 minute after aeration is stopped; taking out upper enriched [Bmim]BF4 phase by a burette when no air bubble exists; adding a certain amount of 75 percent sulphuric acid and 12 to 19 mL/mg of ROX into the sublation column to perform a color development reaction at room temperature for 0 to 70 minutes; analyzing and determining the content of the solution by using a molecule fluorescence photometry in 350nm excitation wavelength and 508nm emission wavelength. The method optimizes the best condition of sublation, and carries out separation/enrichment analysis on the trace roxithromycin in an actual environmental water sample by combining the molecule fluorescence photometry under an optimized testing condition.